Document and Entity Information [Abstract] Document Type Entity Registrant Name Entity Central Index Key Document Period End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets Held-for-sale, Not Part of Disposal Group, Current Asset held for sale Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Restricted Cash, Noncurrent Restricted cash Restricted cash Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity (deficit) Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Accounts payable Accrued Liabilities, Current Accrued expenses Total Short-term Debt Carrying amount Short-term debt, net Derivative Liability, Current Derivative liabilities Operating Lease, Liability, Current Operating lease obligation Current lease obligations Finance Lease, Liability, Current Financing lease obligation Fair value as of the balance sheet date of warrant that is identified as embedded derivative. Embedded Derivative Fair Value Of Embedded Derivative Liability, Warrants Short-term warrant liability Represents the amount of deferred grant proceeds. Deferred Grant Proceeds Current Deferred grant proceeds Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Noncurrent liabilities Deferred Rent Credit, Noncurrent Deferred rent Operating Lease, Liability, Noncurrent Operating lease obligation, less current portion Non-current lease obligations Finance Lease, Liability, Noncurrent Financing lease obligation, less current portion Long-term Debt, Excluding Current Maturities Long term debt, net Liabilities, Noncurrent Total noncurrent liabilities Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 10) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' deficit Preferred Stock, Value, Issued Convertible preferred stock, $0.01 par value, 10,000,000 shares authorized, 7.0 and zero issued and outstanding at September 30, 2019 and December 31, 2018 Common Stock, Value, Issued Common stock, 200,000,000 ($0.01 par value) authorized and 10,013,605 and 4,960,552 issued and outstanding at September 30, 2019 and December 31, 2018 Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Additional Paid in Capital Additional paidin capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Ending balance Beginning balance Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Preferred Stock, Par or Stated Value Per Share Convertible Preferred stock, par value Preferred Stock, Shares Authorized Convertible Preferred stock, Shares authorized Preferred Stock, Shares Issued Convertible Preferred stock, shares issued Preferred Stock, Shares Outstanding Convertible Preferred stock, shares outstanding Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Par or Stated Value Per Share Common stock, par value (dollars per share) Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense) Liabilities, Fair Value Adjustment Change in fair value of derivative liability Change in fair value of derivative liabilities Amount of gain (loss) on conversion of debt. Gains (Losses) on Conversion of Debt Loss on debt conversion Loss on debt conversion Investment Income, Interest Interest income Interest Expense Interest expense Other Nonoperating Income (Expense) Other income (expense) Nonoperating Income (Expense) Total other income (expense) Net Income (Loss) Attributable to Parent Net Loss Net loss Net loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract] Other comprehensive income (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Earnings Per Share, Basic and Diluted Net loss per share of common stock - basic and diluted Net loss per shares of common stock-basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average shares of common stock outstanding Weighted average shares outstanding - basic and diluted CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statement [Table] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Ending balance (in shares) Beginning balance (in shares) Equity impact of the value of stock issued during the period pursuant to reverse asset acquisition. Stock Issued During Period, Value, Reverse Asset Acquisition Issuance of stock for reverse asset acquisition, net of $5.0 million of costs Number of shares issued during the period pursuant to reverse asset acquisition. Stock Issued During Period, Shares, Reverse Asset Acquisition Issuance of stock for reverse asset acquisition, net of $5.0 million of costs (in shares) Equity impact of the value of stock issued during the period pursuant to pre-merger. Stock Issued During Period, Pre Merger, Value Issuance of common stock under Pre-Merger Financing, net of $1.7 million of costs Number of shares of stock issued during the period, pursuant to pre-merger. Stock Issued During Period, Pre Merger, Shares Issuance of common stock under Pre-Merger Financing, net of $1.7 million of costs (in shares) APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of debt Stock Issued During Period, Shares, Conversion of Convertible Securities Common stock issued upon conversion Conversion of debt (in shares) Stock Issued During Period, Value, New Issues Equity transactions Stock Issued During Period, Shares, New Issues Equity transactions (in shares) The amount of costs related to issuance of stock under reverse asset acquisition. Costs Related to Issuance of Stock Under Reverse Asset Acquisition Issuance costs under reverse asset acquisition The amount of costs related to issuance of stock under pre-merger. Costs Related to Issuance of Stock Under Pre Merger Issuance costs under pre-merger CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation expense Amount of non-cash interest expense during the period. Non-Cash Interest Expense Noncash interest expense Share-based Payment Arrangement, Expense Stockbased compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Change during the period in carrying value for all deferred rent. Increase (Decrease) in Deferred Rent Deferred rent Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Acquire Investments Payment of reverse asset acquisition costs Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Finance Lease, Principal Payments Financing lease principal payments Payments of Debt Issuance Costs Payment of debt issuance costs Issuance costs Proceeds from Convertible Debt Proceeds from issuance of convertible debt Repayments of Convertible Debt Repayment of convertible debt Payments of Stock Issuance Costs Payment of equity issuance costs Equity issuance costs paid in cash The cash inflow from the pre-merger financing during the period. Proceeds from Pre Merger Financing, Financing Activities Proceeds from Pre-Merger Financing Proceeds from Issuance or Sale of Equity Proceeds from stock subscription Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of changes in exchange rate on cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash Total cash, cash equivalents and restricted cash Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of non-cash transactions: Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Purchase of fixed assets by entering into capital lease (Note 10) Debt Conversion, Original Debt, Amount Conversion of convertible notes (Note 9) Debt Conversion, Converted Instrument, Amount Conversion of convertible promissory note (Note 9) Amount of noncash or part noncash amount of deferred transaction cost. Noncash Or Part Noncash Amount of Deferred Transaction Cost Equity issuance costs (Note 4) Amount of noncash lessee's right-to-use underlying asset under operating lease. Noncash or Part Noncash, Operating Lease, Right-of-Use Asset Right-of-use asset related to operating leases (Note 10) The amount of deferred equity issuance cost that were incurred during a noncash or partial noncash transaction. Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction Reverse asset acquisition costs (Note 4) Nature of Business Nature of Operations [Text Block] Nature of Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Recent Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Recent Accounting Pronouncements Merger and Financing Mergers, Acquisitions and Dispositions Disclosures [Text Block] Merger and Financing Net Loss Per Share of Common Stock Earnings Per Share [Text Block] Net Loss Per Share of Common Stock License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] License and Collaboration Agreements Balance Sheet Detail Accounts Payable and Accrued Liabilities Disclosure [Text Block] Balance Sheet Detail Equity Transactions Stockholders' Equity Note Disclosure [Text Block] Equity Transactions Debt Debt Disclosure [Text Block] Debt Commitments Commitments and Contingencies Disclosure [Text Block] Commitments No definition available. Pre-Merger Financing Warrants The entire disclosure relating to pre-merger warrants Pre-Merger Financing Warrants [Text Block] Pre-Merger Financing Warrants Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting [Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Principles of Consolidation Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation and Transactions Use of Estimates, Policy [Policy Text Block] Use of Estimates Represents asset held for sale. Asset Held For Sale [Policy Text Block] Asset Held for Sale Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Disclosure of accounting policy for financial instruments indexed to and potentially settled in common stock. Derivative Instruments and Hedging Activities Disclosure [Policy Text Block] Financial Instruments Indexed to and Potentially Settled in Common Stock Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Tabular disclosure of the components of cash and cash equivalents, restricted cash. Schedule of Cash and Cash Equivalents, Restricted Cash [Table Text Block] Schedule of cash, cash equivalents, and restricted cash Disclosure of Long Lived Assets Held-for-sale [Table Text Block] Summary of assets and liabilities to be sold pursuant to Asset Purchase Agreement Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted earnings per share of common stock Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument Name [Domain] Debt Instrument, Name [Domain] Convertible Debt [Member] Convertible Notes Promissory notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Convertible Promissory Notes [Member] Convertible Promissory Notes Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior Secured Convertible Notes [Member] Senior Secured Convertible Notes Debt Instrument [Line Items] Debt Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Schedule of principal, imbedded derivatives and carrying value of debts The tabular disclosure of the change of the embedded derivative during the period. Changes In Fair Value Of Embedded Derivative [Table Text Block] Schedule of changes of embedded derivative of convertible notes Lease, Cost [Table Text Block] Schedule of components of lease expense Tabular disclosure of balance sheet information related to leases. Supplemental balance sheet information leases [table text block] Schedule of supplemental balance sheet information related to leases Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Supplemental cash flow information Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of maturities of operating leases Finance Lease, Liability, Maturity [Table Text Block] Schedule of maturities of finance leases Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of reconciliation of Series B Warrant liability measured at fair value using Level 3 significant unobservable inputs Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Nature of Business Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split ratio The exchange rate of share issued to shares surrendered by stockholder of the acquired entity in a business combination. Business Combination, Issued Shares Exchange Rate Shares issued exchange rate to former Ocugen's stockholders Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Cash, cash equivalents and restricted cash reconciliation: New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Type Of Adoption [Member] Type of Adoption [Domain] Accounting Standards Update201602 [Member] Accounting Standards Update 2016-02 New Accounting Pronouncements or Change in Accounting Principle [Line Items] RECENT ACCOUNTING PRONOUNCEMENTS Operating Lease, Right-of-Use Asset Right-of-use assets, net Operating Lease, Liability Present value of minimum lease payments Lease liability Disclosure of information about reverse merger and financing. Reverse Merger And Financing Disclosure [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reverse Merger And Financing Disclosure [Line Items] Reverse Merger and Financing Number of shares agreed to issue prior to the merger to investors. Number of Shares Agreed to Issue Prior to Merger to Investors Number of shares agreed to issue immediately prior to the merger The number of converted common shares, which the investors have right to receive pursuant to the exchange rate in the Merger, as agreed to be issued by the accounting acquirer to the investors immediately prior to the Merger. Number Of Converted Initial Shares Agreed To Issue Prior To Merger To Investors Number of converted initial shares, agreed to be issued Number of additional shares agreed to issue prior to the merger to Investors. Number of Additional Shares Agreed to Issue Prior to Merger to Investors Number of shares in the form of escrow agreed to issue immediately prior to the merger The number of converted common shares, which the investors have right to receive pursuant to the exchange rate in the Merger, as agreed to be deposited in escrow by the accounting acquirer. Number Of Converted Additional Shares Agreed To Issue Prior To Merger To Investors Number of converted additional shares in the form of escrow agreed to issue immediately prior to the merger Sale of Stock, Consideration Received Per Transaction Sale of stock, consideration received Aggregate purchase price The amount of acquisition costs incurred during the period related to merger. Merger Acquisition Costs Incurred Acquisition cost incurred Proceeds from Warrant Exercises Repayments of Senior Debt Repayment of senior secured notes Amount of net proceeds received from reverse merger. Net Proceeds from Reverse Merger Net proceeds from pre-merger financing The amount of stock issuance costs recognized during the period. Stock Issuance Costs Recognized Equity issuance cost Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Equity issuance costs paid with equity Noncontrolling Interest, Ownership Percentage by Parent Ownership (as a percent) Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Merger and Financing Business Combination, Acquisition Related Costs Acquisition cost incurred Payments for Merger Related Costs Acquisition cost paid in cash Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with merger. Adjustments to Additional Paid in Capital, Merger Related Costs Acquisition cost paid with equity The carrying value as of the balance sheet date of the assets held for sale. Assets Held For Sale Asset held for sale Net Assets Net assets acquired The amount of cash consideration agreed under the asset purchase agreement. Asset purchase agreement, cash consideration Asset Purchase Agreement, cash consideration Percentage of asset purchase agreement that the purchase price increases per month between October 31, 2019 and the closing date if agreement is not terminated. Percentage of Increase In Purchase Price Of Asset Per Month Percentage of increase in purchase price of asset per month Proceeds from License Fees Received Upfront cash payment received for license granted to MEDINET Assets Held-for-sale, Long Lived, Fair Value Disclosure Quoted price of assets held for sale of NeoCart Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Stock Option [Member] Options to purchase Common Stock Warrant [Member] Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Earnings Per Share Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Potentially dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding The per share represents the information pertaining to reverse stock split exchange ratio. Reverse Stock Split Exchange Ratio Exchange rate per share Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Arrangements And Nonarrangement Transactions [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents co-development and commercialization agreement (the "Agreement") with CanSino Biologics Inc. ("CanSino") with respect to the development and commercialization of the gene therapy product candidate, OCU400, for the treatment of NR2E3 Mutation-Associated Retinal Degeneration, Leber Congenital Amaurosis, Bardet-Biedl Syndrome and Rhodopsin Mutation-Associated Retinal Degeneration. Collaboration Agreement With Cansino Biologics [Member] Collaboration Agreement with CanSino Biologics Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] License agreements: Represents the term of agreement or milestone. Collaboration agreement term Term (in years) Period within which a party to collaboration agreement is to provide the entity statement of development costs after termination of agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Collaboration Agreement, Termination, Development Cost Statement Period within with Cansino to provide development cost statement Period within which the entity is to reimburse a party to collaboration agreement of development costs after a statement of such is provided upon termination of the agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Collaboration Agreement, Termination, Development Cost Payment Period within which to reimburse Cansino of development costs Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Research And Development Expenses Current Research and development Amount of obligations incurred classified as Clinical. Accounts Payable Clinical Clinical Amount of obligations incurred classified as Consulting. Accounts payable Consulting Consulting Employee-related Liabilities, Current Employee-related Accrued Professional Fees, Current Legal Schedule of Subsidiary or Equity Method Investee [Table] Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] Investor [Member] Existing investors - Subscription Agreement Private Placement [Member] Financial advisor - Service Agreement Subsidiary or Equity Method Investee [Line Items] Equity transactions Sale of Stock, Number of Shares Issued in Transaction Shares issued (in shares) Sale of Stock, Price Per Share Price per share Represents borrowings from the U.S. government's Immigrant Investor Program, commonly known as the EB 5 program (the "EB 5 Program"). E B5 Program Borrowings [Member] EB-5 Loan Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing The amount of borrowing that can be borrowed each draw from a line of credit Line Of Credit Borrowing Each Draw Borrowing increments Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Proceeds from Loans Amount borrowed Amortization of Debt Issuance Costs Amortization of debt issuance costs Long-term Line of Credit Principal outstanding Interest Expense, Debt Accrued interest Interest Payable Total accrued interest Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in January 2018. Convertible Debt January2018 [Member] Convertible Note - January 2018 Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in June 2018. Convertible Debt June2018 [Member] Convertible Note - June 2018 Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in November 2018. Convertible Debt November2018 [Member] Convertible Note - November 2018 Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in December 2018. Convertible Debt December2018 [Member] Convertible Note - December 2018 Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in January 2019. Convertible Debt January2019 [Member] Convertible Note - January 2019 Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in February 2019. Convertible Debt February2019 [Member] Convertible Note - February 2019 Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Title of Individual [Domain] Director [Member] Board members Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Conversion feature of the convertible debt that is considered as an embedded derivative of the debt. Convertible Debt Conversion Feature [Member] Convertible Debt, Conversion Feature The change in control feature of the convertible debt that is considered as an embedded derivative of the debt. Convertible Debt Change Control Feature [Member] Change in Control feature Debt Instrument, Face Amount Note principal amount Convertible Debt Note principal outstanding Embedded Derivative, Fair Value of Embedded Derivative Liability Fair value of embedded derivative Fair value of embedded derivative Fair value of embedded derivative Fair value of embedded derivative Debt Issuance Costs, Gross Debt issuance costs Long-term Debt Carrying amount Debt Instrument, Term Maturity term (in months) Redemption multiple of debt's principal and unpaid interest upon default. Debt, Redemption Multiple Upon Default Redemption multiple upon default The minimum amount of equity financing that automatically convert the same class of equity as those issued. Convertible Debt, Equity Financing Trigger Equity financing proceeds that triggers conversion Percentage of discount of the convertible debt that automatically convert the same class of equity as those issued to the lowest price per share being paid by investors in the equity financing. Convertible Debt, Equity Financing Triggered, Discount Conversion price discount per original agreement (as a percent) Amortization of Debt Discount (Premium) Accretion of the original issue discount Accretion of debt discount Fair value of the embedded derivative or group of embedded derivatives generated during the period. Embedded Derivative, Fair Value of Embedded Derivative Liability, Activity Fair value at issuance Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Change in fair value of embedded derivatives Actual percentage of discount of the convertible debt that converted to the same class of equity as those issued to the lowest price per share being paid by investors in the equity financing per revised agreement. Convertible Debt, Equity Financing Triggered, Revised Agreement, Actual Discount Actual conversion price discount per revised agreement (as a percent) Debt Instrument, Convertible, Conversion Price Conversion price per share (USD per share) Gain (Loss) on Extinguishment of Debt Extinguishment of debt loss Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Increase in Additional paid-in capital from conversion The redemption feature of debt that is considered as an embedded derivative of the debt. Debt Redemption Feature [Member] Embedded Redemption Feature Debt Instrument, Unamortized Discount Original Issue Discount Issued discount The amount of debt that will offset against receipts from investors prior to effectivity of the merger. Debt Offset Against Investors Prior To Merger Amount that will offset from the remaining amount to be received from the investors Lessee, Lease, Description [Table] Statistical Measurement [Axis] Range [Member] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Lessee, Lease, Description [Line Items] Leases Lessee, Operating Lease, Term of Contract Leases, term of contract (in years) Operating Lease, Cost Operating lease cost Variable Lease, Cost Variable lease cost Lease, Cost Total lease cost Operating Lease, Payments, Use Operating cash flows from operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new operating liabilities Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease terms-operating leases (years) Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate-operating leases Operating Leases, Future Minimum Payments, Remainder of Fiscal Year Remainder of 2019 Operating Leases, Future Minimum Payments, Due in Two Years 2020 Operating Leases, Future Minimum Payments, Due in Three Years 2021 Operating Leases, Future Minimum Payments, Due in Four Years 2022 Operating Leases, Future Minimum Payments Due Total Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: present value adjustment Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Equipment under finance leases. Finance Leased Equipment [Member] Specialized research equipment Property, Plant and Equipment [Line Items] Finance leases Lessee, Finance Lease, Term of Contract Finance lease, term (in years) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated amortization Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Amortization Lessee, Finance Lease, Discount Rate Interest rate (as a percent) Finance Lease, Liability, Payments, Remainder of Fiscal Year Remainder of 2019 Finance Lease, Liability, Payments, Due Year Two 2020 Finance Lease, Liability, Payments, Due Year Three 2021 Finance Lease, Liability, Payment, Due Total Finance Lease, Liability, Undiscounted Excess Amount Less: present value adjustment Finance Lease, Liability Present value of minimum lease payments Fair Value, by Balance Sheet Grouping [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Pre-Merger Financing Warrants The number of trading days after the consummation of merger, when the Warrants will be issued, as per the reverse merger agreement. Class Of Warrant Or Rights, Issuance, Number Of Trading Days After The Consummation Of Merger The exercise of the Pre-Merger Financing Warrants if, as a result of such exercise, the holder, together with its affiliates would beneficially own in excess percentage one of the outstanding common stock. Percentage Of Excess Common Stock On Pre-Merger Financing Warrants One Percentage of excess common stock on pre-merger financing warrants exercised one The exercise of the Pre-Merger Financing Warrants if, as a result of such exercise, the holder, together with its affiliates would beneficially own in excess percentage two of the outstanding common stock. Percentage Of Excess Common Stock On Pre-Merger Financing Warrants Two Percentage of excess common stock on pre-merger financing warrants exercised two If company fails to issue to a holder of the Pre-Merger Financing Warrants the number of shares of common stock to which such holder is entitled upon such holder's exercise of the such warrants, then company shall be obligated to pay the holder on each day while such failure is continuing an amount equal to percentage of the market value of the undelivered shares determined using any trading price of the common stock. Percentage Of Amount On Market value For Failure To Issue Common Stock On Pre-Merger Financing Warrants Percentage of amount on market value for failure to issue common stock on pre-merger financing warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Initial exercise price Term of the warrants or rights issued. Class Of Warrant Or Right, Term Of Warrants or Rights Term of the warrants The percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market for the first three trading days immediately following the closing date of the Pre-Merger Financing as threshold to release converted additional shares. Converted Additional Shares, Threshold Release Trigger Percentage of volume-weighted average trading price of a share of common stock that triggered release od converted additional shares The price over which the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market to release converted additional shares is determined. Converted Additional Shares, Threshold Release Trigger Price Price over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares The period over which the percentage of the volume-weighted average trading price of a share of common stock as quoted on the Nasdaq Capital Market to release converted additional shares is determined, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Converted Additional Shares, Threshold Release Trigger Period Period over which trading price of common stock as quoted on the Nasdaq Capital Market was considered for the release of converted additional shares The dividing factor considered for determination of exercise price of warrants. Class Of Warrant Or Right, Exercise Price Determination, Dividing Factor Warrants, exercise price determination, dividing factor The trading day after which the warrants will expire. Class Of Warrant Or Right, Condition For Expiration, Trading Day Warrants Expiration, trading day Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of common shares in to which the warrants are exercisable The number of trading days considered for determination of exercise price of warrants. Class Of Warrant Or Right, Exercise Price Determination, Number Of Trading Days Considered Warrants, exercise price determination, number of trading days Class of Warrant or Right, Outstanding Number of warrants outstanding Warrants and Rights Outstanding, Measurement Input Warrants fair value estimate volatility Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Reconciliation of Series B Warrant liability Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Balance at end Balance at beginning Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues Fair value at issuance Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) Change in fair value of embedded derivatives Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Events Maximum number of additional warrants or rights issuable. Maximum Class Of Warrants or Rights Issuable Maximum additional warrants issuable Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent events The number of shares to be sold by selling shareholders as per the Form S-3 Registration Statement. Common Stock, Shares To Be Sold By Selling Shareholders Common stock, Shares to be sold by selling shareholders Stock Repurchase Program, Authorized Amount Share repurchase program, Authorized amount Proceeds from Issuance of Warrants Gross proceeds on issue of warrants Number of warrants exercised. Class Of Warrant Or Right Number Exercised Number of warrants exercised Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of common stock issued for each warrant Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Preferred Stock [Member] Preferred Stock Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-in Capital Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income (Loss) Retained Earnings [Member] Accumulated Deficit Legal Entity [Axis] Entity [Domain] Entity [Domain] Represents Histogenics Corporation. Histogenics Corporation [Member] Histogenics Represents the information pertaining to Securities Purchase Agreement entered with several investors. Securities Purchase Agreement [Member] Financing SPA Information pertaining to series A and C warrants. Series Warrants And Series C Warrants [Member] Series A warrants And Series C warrants This member stands for Series B Warrants. Series B Warrants [Member] Series B Warrants Equity holders of Ocugen, Inc. immediately before the merger. Equity Holders Of Ocugen Inc Per Merger [Member] Former Ocugen equity holders Equity holders of Histogenics Corporation immediately before the merger. Equity Holders Of Histogenics Corporation [Member] Stockholders of Histogenics immediately before the Merger Ownership [Axis] Ownership [Domain] Ownership [Domain] Business Acquisition [Axis] Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Inputs Level2 [Member] Level 2 This member stands for Series A Warrants. Series Warrants [Member] Series A Warrants This member stands for Series C Warrants. Series C Warrants [Member] Series C Warrants Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in May 2019. Senior Secured Convertible Notes May2019 [Member] Senior Secured Convertible Notes - May 2019 Senior secured borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock, issued in June 2019. Senior Secured Convertible Notes June2019 [Member] Senior Secured Convertible Notes - June 2019 Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input Price Volatility [Member] Price Volatility